Clinical Trial

Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

Name: Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease — clinical trial record (NCT04873258)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MASLD

Recruiting

View on ClinicalTrials.gov →

Summary

A generic screening study to establish structural and/or functional baselines of specific organs.

Protocol Amendment History 6 amendments

This ClinicalTrials.gov record has been amended 6 times since 2021-04-29; most recent amendment 2025-07-18.

Trial Details

NCT Number	NCT04873258
Lead Sponsor	Richmond Research Institute Collaborators: Richmond Pharmacology Limited
Conditions	Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity and Obesity-related Medical Conditions
Enrollment	2,000 participants
Start Date	2019-09-27
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-07-23